Bambusa Therapeutics (NASDAQ:BBTX) Director Purchases $6,639,386.60 in Stock

Bambusa Therapeutics, Inc. (NASDAQ:BBTX) Director Ra Capital Management, L.P. bought 453,820 shares of the firm’s stock in a transaction that occurred on Friday, October 30th. The stock was bought at an average cost of $14.63 per share, for a total transaction of $6,639,386.60. Following the completion of the acquisition, the director owned 453,820 shares in the company, valued at $6,639,386.60. This trade represents a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Monday, November 2nd, Ra Capital Management, L.P. purchased 2,500,000 shares of Bambusa Therapeutics stock. The shares were bought at an average cost of $16.00 per share, with a total value of $40,000,000.00.

Bambusa Therapeutics Trading Down 1.4%

NASDAQ:BBTX opened at $15.85 on Friday. Bambusa Therapeutics, Inc. has a 52-week low of $13.60 and a 52-week high of $17.42.

Bambusa Therapeutics Company Profile

Bambusa Therapeutics, Inc is a clinical-stage biopharmaceutical company developing next-generation, long-acting precision bispecific antibodies designed to redefine standards of care in immunology and inflammation and fundamentally improve patient quality of life. Its pipeline includes BBT001, BBT002, BBT003 and BBT004. Bambusa Therapeutics, Inc is based in BOSTON.